What is embryonal rhabdomyosarcoma?
Embryonal rhabdomyosarcoma (ERMS) is a cancer that develops from immature cells that would normally grow into skeletal muscle, the muscle we use to move. It is the most common type of rhabdomyosarcoma, which in turn is the most common soft tissue sarcoma in children and teenagers.
ERMS usually affects young children, most often before the age of 5. It typically starts in the head and neck (for example around the eye or behind the nose) or in the bladder, prostate, vagina or tissues next to the testicle. It can, however, appear almost anywhere in the body, including places that have no skeletal muscle.
Under the microscope, the tumour cells look like the muscle cells of an early embryo, which is where the name comes from. Unlike alveolar rhabdomyosarcoma, ERMS does not carry a PAX3::FOXO1 or PAX7::FOXO1 gene fusion, so doctors also call it fusion-negative rhabdomyosarcoma.
With modern combined treatment, most children with ERMS that has not spread are cured. Treatment is complex and is best given at a specialist children’s cancer centre, usually within a clinical trial or a national treatment protocol.
1. How common is it?
Rhabdomyosarcoma is rare. According to the US National Cancer Institute (NCI), about 4.6 children and teenagers per million under the age of 20 are diagnosed each year, which is around 350 new cases a year in the United States. Embryonal tumours make up about 60-75% of rhabdomyosarcoma in children and teenagers.
| Feature | Details |
|---|---|
| Share of childhood cancer | Rhabdomyosarcoma accounts for about 3% of cancers in children under 15 |
| Peak age | 0-4 years, about 4 cases per million children per year; less common in teenagers |
| Sex | Boys are affected about 1.5 times as often as girls |
| Most common sites | Head and neck, including the orbit and parameningeal areas; genitourinary tract |
| Adults | ERMS can occur in adults but is uncommon; adult rhabdomyosarcoma is more often pleomorphic |
2. Causes and risk factors
In most children, ERMS appears for no known reason, and nothing the child or parents did caused it. A small proportion of cases are linked with an inherited condition that raises the risk of cancer.
| Condition | Gene involved | Notes |
|---|---|---|
| Li-Fraumeni syndrome | TP53 | Often linked with the anaplastic form of ERMS in young children |
| DICER1 syndrome | DICER1 | Especially ERMS of the cervix in teenage girls and young women |
| Neurofibromatosis type 1 | NF1 | Pale brown skin patches (cafe-au-lait spots) and nerve tumours |
| Costello syndrome | HRAS | Rare growth and developmental disorder |
| Noonan syndrome | Several RAS-pathway genes | Heart defects, short stature and typical facial features |
| Beckwith-Wiedemann syndrome | Changes at chromosome 11p15 | More closely linked with Wilms tumour and hepatoblastoma |
A study by the Children’s Oncology Group (COG) found a cancer-predisposing inherited variant in about 1 in 10 children with ERMS. A high birth weight has also been linked with a slightly higher risk. Families may be offered genetic counselling, particularly if the child is very young, the tumour shows anaplasia, or there is a family history of cancer.
Genetic changes in the tumour
ERMS cells commonly show loss of genetic material on the short arm of chromosome 11 (11p15) and extra copies of chromosome 8. About half of tumours have a change in a gene of the RAS pathway, such as NRAS, KRAS, HRAS or NF1, which drives cell growth.
TP53 changes are found in about 10-15% of fusion-negative tumours and are linked with a poorer outcome. Future COG trials plan to use TP53 status and MYOD1 status to help assign risk groups.
3. How does it look?
ERMS usually shows itself as a swelling or lump, but its appearance depends very much on where it grows. Because children cannot always describe symptoms, parents are often the first to notice that something looks different.
3.1 On the outside of the body
- Around the eye (orbit): the eye may bulge forward or be pushed to one side, and the eyelid may be swollen or droop. The swelling can develop over a few weeks.
- Head and neck: a firm, painless lump on the cheek, neck or scalp, or a swelling inside the mouth or throat.
- Next to the testicle (paratesticular): a painless, firm swelling in the scrotum, separate from or attached to the testicle.
- Arms, legs and trunk: a lump under the skin or deep in a muscle. The skin over it usually looks normal.
3.2 The grape-like (botryoid) pattern
In hollow organs lined by a moist surface, ERMS can grow as soft, shiny, grape-like clusters. This pattern used to be called sarcoma botryoides, from the Greek word for a bunch of grapes.
It is typically seen in the vagina of girls under 3, in the bladder, the nasopharynx and the bile ducts. A grape-like mass may be seen at the opening of the vagina, often with bleeding or discharge.
3.3 On scans
On MRI or CT, ERMS appears as a soft tissue mass that may push aside or grow into nearby structures. In the head, doctors look closely for growth through the base of the skull, which changes treatment.
3.4 Under the microscope
The pathologist sees small, round and spindle-shaped cells mixed with larger cells that have bright pink cytoplasm, called rhabdomyoblasts. Cell-rich areas often alternate with loose, jelly-like (myxoid) areas, and occasionally cross-stripes like those in normal muscle are visible.
In the botryoid pattern, there is a dense band of tumour cells just beneath the surface lining, called the cambium layer. About 13% of ERMS show anaplasia, meaning very large, irregular nuclei.
Special stains confirm muscle origin: the tumour cells are positive for desmin, myogenin and MyoD1. In ERMS, myogenin staining is usually patchy, while strong, widespread staining suggests the alveolar type, so a FOXO1 fusion test by FISH or RT-PCR is used to settle the subtype.
3.5 How it is classified
The 5th edition of the WHO classification of soft tissue tumours (2020) recognises four types of rhabdomyosarcoma: embryonal, alveolar, spindle cell/sclerosing and pleomorphic. Botryoid tumours are now counted as a pattern of ERMS rather than a separate type.
Spindle cell/sclerosing rhabdomyosarcoma is a separate category. It includes infant tumours with VGLL2 or NCOA2 fusions, which usually do well, and tumours with a MYOD1 mutation, which behave aggressively.
4. Symptoms
Symptoms depend on the site of the tumour and on what it presses on. Many children feel well apart from a lump, and general symptoms such as fever or weight loss are less common than in some other childhood cancers.
| Site | Common symptoms and signs |
|---|---|
| Orbit | Bulging eye, swollen or drooping eyelid, double vision, eye pushed out of position |
| Parameningeal (nose, sinuses, middle ear, area behind the nose) | Blocked nose, nosebleeds, nasal discharge, ear discharge or hearing loss, facial swelling, headache, facial weakness or a squint from nerve involvement |
| Other head and neck | Painless lump on the face, cheek, neck or in the mouth or throat; hoarseness or difficulty swallowing |
| Bladder and prostate | Blood in the urine, difficulty passing urine, frequent urination, a lump felt in the lower abdomen, constipation |
| Vagina, vulva, cervix or uterus | Vaginal bleeding or discharge, a grape-like mass at the vaginal opening |
| Paratesticular | Painless swelling in the scrotum |
| Bile ducts | Yellowing of the skin and eyes (jaundice), pale stools, dark urine, itching, tummy pain |
| Arms, legs, trunk, abdomen | Growing lump, sometimes painful; swelling of the tummy; constipation or urinary problems from a pelvic mass |
If the cancer has spread, it most often goes to the lungs, lymph nodes, bones and bone marrow. Signs can include cough or breathlessness, bone pain, tiredness and paleness from low blood counts.
When to see a doctor
Take your child to a doctor if a lump grows or does not go away within a few weeks, especially if it is firm and painless. Blood in the urine, vaginal bleeding or a mass in a young girl, a bulging eye, or a nosebleed or blocked nose on one side that does not settle also need prompt checking.
Most lumps in children turn out to be harmless. However, a lump that keeps growing should always be assessed, and imaging and a biopsy may be needed.
5. Diagnosis
Diagnosis and staging are usually done before any major surgery, so that the treatment team can plan the best approach from the start.
| Test | Purpose |
|---|---|
| MRI or CT of the primary site | Shows the size of the tumour and its relation to nearby organs, nerves and blood vessels |
| Biopsy | Core needle or open biopsy to obtain enough tissue for diagnosis and genetic tests |
| Pathology and FOXO1 testing | Confirms rhabdomyosarcoma with desmin, myogenin and MyoD1 stains; FISH or RT-PCR checks for a FOXO1 fusion |
| CT of the chest | Looks for spread to the lungs |
| PET-CT | Helps find spread to lymph nodes and distant sites; recommended in current COG protocols |
| Bone marrow tests and bone scan | Used in selected patients to look for spread to marrow and bone |
| Lumbar puncture | For parameningeal tumours, to check the fluid around the brain and spinal cord |
| Lymph node sampling | Sentinel node biopsy for limb and trunk tumours; node sampling in the abdomen for boys aged 10 and older with paratesticular tumours |
For a scrotal swelling, the testicle and tumour are removed through a cut in the groin (radical inguinal orchiectomy). A biopsy through the skin of the scrotum is avoided because it can spread tumour cells.
6. Staging and risk groups
Rhabdomyosarcoma uses its own staging systems rather than the adult soft tissue sarcoma system. Doctors combine three pieces of information: the stage, the clinical group and the risk group.
6.1 Stage (before treatment)
The stage depends on the site of the tumour, its size, whether lymph nodes look involved and whether it has spread. Favourable sites are the orbit, the head and neck outside the parameningeal area, and the genitourinary tract other than the bladder and prostate. All other sites, including the bile ducts in current COG definitions, are unfavourable.
| Stage | Site | Size | Lymph nodes | Distant spread |
|---|---|---|---|---|
| 1 | Favourable | Any | Any | None |
| 2 | Unfavourable | 5 cm or smaller | Not involved | None |
| 3 | Unfavourable | 5 cm or smaller | Involved | None |
| 3 | Unfavourable | Larger than 5 cm | Any | None |
| 4 | Any | Any | Any | Present |
6.2 Clinical group (after first surgery or biopsy)
| Group | Definition | Share of patients |
|---|---|---|
| I | Localised tumour completely removed | About 15% |
| II | Tumour removed, but microscopic tumour left behind, or involved regional nodes removed | About 16% |
| III | Only a biopsy, or tumour removed incompletely with visible tumour left | About 50% |
| IV | Distant spread at diagnosis | About 20% |
6.3 Risk group
The COG combines stage, group and fusion status into risk groups that decide treatment. For fusion-negative tumours such as ERMS, the groups are summarised below.
| Risk group | Fusion-negative tumours included |
|---|---|
| Very low risk | Stage 1, Group I (TP53 and MYOD1 not altered) |
| Low risk | Stage 1, Group II or Group III orbit; Stage 2, Group I or II |
| Intermediate risk | Stage 1, Group III outside the orbit; Stage 2 or 3, Group III; Stage 3, Group I or II; Stage 4 in children under 10 |
| High risk | Stage 4 in patients aged 10 or older |
European groups such as the European paediatric Soft tissue sarcoma Study Group (EpSSG) use slightly different definitions, so the same child may be placed in a different named group in Europe.
7. Treatment
Every child with ERMS needs chemotherapy, combined with local treatment of the tumour by surgery, radiotherapy or both. The aim is to cure the cancer while keeping long-term side effects as low as possible.
7.1 Chemotherapy
| Regimen | Drugs | Typical use | Key facts |
|---|---|---|---|
| VA | Vincristine, dactinomycin | Very low and low risk | EpSSG gave 22 weeks of VA to young children with small, low-risk tumours: 95.5% event-free, 100% alive |
| VAC | Vincristine, dactinomycin, cyclophosphamide | Low and intermediate risk | Long-standing North American standard; in COG ARST0331, low-risk subset 1 had 89% failure-free and 98% overall survival at 3 years |
| VAC/VI | VAC alternating with vincristine and irinotecan | Intermediate risk (COG) | No better than VAC in ARST0531, but less blood toxicity and half the cyclophosphamide dose |
| IVA | Ifosfamide, vincristine, dactinomycin | Higher-risk localised disease (Europe) | Adding doxorubicin did not improve results in the EpSSG RMS 2005 trial |
| Maintenance | Vinorelbine plus low-dose oral cyclophosphamide | After standard treatment for higher-risk disease | Six months raised 5-year survival from 73.7% to 86.5% in RMS 2005 |
| Intensive combinations | For example VDC/IE, irinotecan, temozolomide | Metastatic or relapsed disease | Benefit mainly in patients with fewer adverse risk factors |
Adding the targeted drug temsirolimus to VAC/VI did not improve outcomes in the COG ARST1431 trial, with 3-year event-free survival of 66.8% versus 64.8%. Drugs aimed at specific gene changes are being tested in trials, but none has yet become standard for newly diagnosed ERMS.
7.2 Surgery
Surgery aims to remove the tumour completely when this can be done without loss of important function or appearance. Many tumours in the head and neck, bladder, prostate and vagina are not removed at diagnosis; chemotherapy shrinks them first.
A delayed operation after initial chemotherapy may allow a lower radiotherapy dose. For bladder and prostate tumours, the goal is to keep a working bladder whenever possible, and operations that remove pelvic organs are now rarely needed.
7.3 Radiotherapy
Most patients need radiotherapy, which is usually given once a day, five days a week, for about five to six weeks. Modern techniques such as intensity-modulated radiotherapy (IMRT) and proton therapy help spare growing tissues.
| Situation | Typical approach |
|---|---|
| Group I ERMS (completely removed) | No radiotherapy needed |
| Group II (microscopic tumour left) | About 36 Gy, or 41.4 Gy if lymph nodes were involved |
| Group III (visible tumour left) | About 50.4 Gy; lower doses after a successful delayed operation |
| Orbit, Group III | 45 Gy if the tumour disappears with chemotherapy; otherwise 50.4 Gy |
| Vagina, bladder and prostate | External radiotherapy or, in some centres, brachytherapy (internal radiotherapy) |
Leaving out radiotherapy in girls with Group III vaginal tumours, combined with lower cyclophosphamide doses, led to more relapses in ARST0331. For this reason, radiotherapy decisions in very young children are made carefully by experienced teams.
7.4 Site-specific points
| Site | Main treatment points |
|---|---|
| Orbit | Biopsy only, then chemotherapy and radiotherapy; the eye is almost always saved |
| Parameningeal | Radiotherapy is nearly always needed; started early if the tumour has grown into the skull base or brain |
| Paratesticular | Groin operation to remove the testicle and tumour; abdominal node sampling for boys aged 10 and older |
| Vagina | Chemotherapy first; surgery or brachytherapy for any remaining tumour |
| Bladder and prostate | Chemotherapy, radiotherapy and organ-sparing surgery where possible |
| Bile ducts | Biopsy, chemotherapy and radiotherapy; major liver surgery is usually not needed |
7.5 Relapsed disease
If ERMS comes back, treatment depends on where it recurs, the time since diagnosis and the treatment already received. Options include chemotherapy combinations with drugs such as vinorelbine, irinotecan or temozolomide, further surgery and radiotherapy, and clinical trials.
8. Prognosis
The outlook for ERMS is generally better than for alveolar rhabdomyosarcoma. In large North American studies of localised disease, about 82% of patients with embryonal tumours were alive at 5 years, compared with 65% for alveolar tumours.
| Factor | Effect on outlook |
|---|---|
| Risk group | Low risk: about 9 in 10 children are free of disease and nearly all are alive at 3 years; intermediate risk: about 65% event-free and 78% alive at 3 years in ARST1431, which also included fusion-positive tumours |
| Age | Best for ages 1-9; less favourable for infants under 1 and for patients over 10 |
| Size | Tumours 5 cm or smaller do better than larger ones |
| Site | Orbit and genitourinary sites outside the bladder and prostate do best |
| Lymph nodes | Involved regional nodes lower the chance of cure |
| Spread at diagnosis | Overall about 1 in 4 metastatic patients are event-free at 3 years; children under 10 with ERMS, especially with spread only to the lungs, do better |
| TP53 or MYOD1 changes | Linked with a higher risk of relapse |
Survival by primary site, based on studies summarised by the NCI, is shown below.
| Primary site | Approximate 5-year survival |
|---|---|
| Orbit | 97% |
| Genitourinary, not bladder or prostate | 89% |
| Bladder and prostate (localised) | 84% |
| Head and neck, not parameningeal | 83% |
| Bile ducts | 77-78% |
| Parameningeal | About 70% |
| Limbs (localised) | 67% |
| Trunk, abdomen, perineum | 67% |
In a large pooled analysis of metastatic rhabdomyosarcoma, the risk factors were age under 1 or 10 and older, an unfavourable primary site, bone or bone marrow involvement, and three or more sites of spread. Children with none of these factors had 50% event-free survival at 3 years, compared with 5% for those with all four. Relapse after five years free of disease is uncommon.
9. Follow-up and late effects
After treatment, children have regular checks with examination and scans, most often every few months in the first years. Most relapses happen within the first three years.
Because treatment is given to growing bodies, survivors need lifelong follow-up, ideally in a late-effects clinic. The Children’s Oncology Group publishes long-term follow-up guidelines that set out which checks are needed.
| Possible late effect | Main cause | Typical checks |
|---|---|---|
| Reduced fertility | Cyclophosphamide, ifosfamide, pelvic radiotherapy | Puberty and hormone checks; fertility advice before treatment where possible |
| Growth problems and uneven bone growth | Radiotherapy | Height, posture and limb length checks |
| Hormone problems | Radiotherapy near the pituitary gland or thyroid | Blood tests for growth hormone, thyroid and other hormones |
| Eye problems, dry eye or cataract | Orbital radiotherapy | Regular eye examinations |
| Hearing loss and dental problems | Head and neck radiotherapy | Hearing tests and dental reviews |
| Bladder and kidney problems | Cyclophosphamide, ifosfamide, pelvic radiotherapy | Urine tests, blood pressure and kidney function |
| Nerve damage | Vincristine, vinorelbine | Checks for numbness, weakness or constipation |
| Second cancers | Radiotherapy, alkylating drugs, inherited predisposition | Skin and site checks; specific screening for inherited syndromes |
10. Living with embryonal rhabdomyosarcoma
A diagnosis of cancer in a child affects the whole family. Treatment can last many months, and the care team usually includes nurses, psychologists, social workers, play specialists and teachers.
- Ask the team about fertility preservation before treatment starts; options depend on the child’s age and sex.
- Report fever promptly during chemotherapy, as low blood counts make infections dangerous.
- Physiotherapy, speech therapy and dental care may be needed after treatment of the head, neck or limbs.
- Keep a summary of the diagnosis and all treatments received, including drug doses and radiotherapy sites, for future doctors.
- Support from children’s cancer charities, parent groups and school liaison services can help families cope.
Resources
- Skapek, S.X. et al. (2019) ‘Rhabdomyosarcoma’, Nature Reviews Disease Primers, 5(1), p. 1.
- Shern, J.F. et al. (2021) ‘Genomic classification and clinical outcome in rhabdomyosarcoma: a report from an international consortium’, Journal of Clinical Oncology, 39(26), pp. 2859-2871.
- Rudzinski, E.R. et al. (2015) ‘The World Health Organization classification of skeletal muscle tumors in pediatric rhabdomyosarcoma: a report from the Children’s Oncology Group’, Archives of Pathology and Laboratory Medicine, 139(10), pp. 1281-1287.
- Haduong, J.H. et al. (2022) ‘An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children’s Oncology Group clinical trials’, Pediatric Blood and Cancer, 69(4), e29511.
- Walterhouse, D.O. et al. (2014) ‘Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group’, Journal of Clinical Oncology, 32(31), pp. 3547-3552.
- Hawkins, D.S. et al. (2018) ‘Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: a report from the Children’s Oncology Group’, Journal of Clinical Oncology, 36(27), pp. 2770-2777.
- Gupta, A.A. et al. (2024) ‘Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children’s Oncology Group’, The Lancet Oncology, 25(7), pp. 912-921.
- Bisogno, G. et al. (2019) ‘Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial’, The Lancet Oncology, 20(11), pp. 1566-1575.
- Oberlin, O. et al. (2008) ‘Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups’, Journal of Clinical Oncology, 26(14), pp. 2384-2389.
- National Cancer Institute (2026) Childhood Rhabdomyosarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/rhabdomyosarcoma-treatment-pdq (Accessed: October 2026).
- National Cancer Institute (2026) Childhood Rhabdomyosarcoma Treatment (PDQ) – Patient Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/patient/rhabdomyosarcoma-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.